- FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks
READ NEWS - FDA Approves the First Treatment for All Hepatitis C Genotypes in Pediatric Patients
READ NEWS - Viral Hepatitis Research Highlights from CROI 2019
READ NEWS - Why Aren't More Users Of Opioids Or Meth Screened For Hepatitis C?
READ NEWS - Study Casts Doubt on Connection Between DAAs and Liver Cancer Risk
READ NEWS - Most At-Risk Young People Are Not Tested for Hepatitis C
READ NEWS - "Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study".
READ NEWS - Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment.
READ NEWS - Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
READ NEWS - Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: A systematic review and meta-analysis
READ NEWS - Oral Hepatitis C Drug Found Safe in Patients With Renal Failure
READ NEWS - When it Comes to Curing Hepatitis C, Your Health Care Provider May Not Need to Be A Specialist
READ NEWS - AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
READ NEWS - Hepatitis C Increases Miscarriages, Pregnancy Risks
READ NEWS - Treatment with DAAs reduces the risk of mortality in the first 18 months after the completion of treatment
READ NEWS - FDA Approves Gilead's Vosevi Combo Pill for Hepatitis C Re-treatment
READ NEWS - FDA OKs new drug to treat all forms of hepatitis C
READ NEWS - Hepatitis C Virus Cases Nearly Triple in 5 years
READ NEWS - Direct-acting antivirals for hepatitis C not linked to higher liver cancer risk in most studies
READ NEWS - Hepatitis Tied to Parkinson’s Risk
READ NEWS - Cirrhosis Increasing Among Hepatitis C Patients, According to Large US Study
READ NEWS - Hepatitis C – Hepatitis Central.Com
READ NEWS - Primary care providers can effectively treat people with hepatitis C
READ NEWS - VA Study Confirms High Cure Rates With Use Of New Hepatitis C Drugs
READ NEWS - Hepatitis C virus and neurological damage
READ NEWS - Over 1 million treated with highly effective hepatitis C medicines
READ NEWS - Gilead and Massachusetts Agree to Rebates for Hep C Drugs
READ NEWS - FDA approves Epclusa
READ NEWS
-
EASL – European Association for the Study of Liver Disease
Amsterdam, Netherlands
April 19, 2017 - April 23, 2017
http://www.easl.eu/discover/events/international-liver-congress -
DIGESTIVE DISEASE WEEK
May 6, 2017 - May 9, 2017
Chicago, IL
http://www.ddw.org/home -
HCV 2017
September 25 – 28, 2017
4th International Symposium
Hyannas, MA
http://www.hcv2017.org/ -
AASLD – The Liver Meeting 2017
October 20 – 24, 2017
Washington, DC
http://www.aasld.org/events-professional-development/liver-meeting
This site complies with the HONcode standard for trustworthy health information:
verify here.
The information provided on this site is intended to support, not replace, the relationship that exists between a patient and his/her physician. Hepatitis C Association does not display commercial content or receive funding from advertising products or services.
Support line: 877-HELP-4-HEP (877-435-7443)
For questions about Harvoni or Sovaldi providers & patients call 1-855-769-7284
Or visit the following websites:
Patient Advocate Foundation call 1-800-532-5274 or visit www.patientadvocate.org
For Questions about Viekira Pak
Call 1-844-2-PROCEED (1-844-277-6233)
or visit www.viekira.com
For questions about Olysio
Call 1-855-65-99747 or visit www.olysio.com
